A Phase 1 Study of Durvalumab and IPH2201 in Adult Subjects With Select Advanced Solid Tumors

Trial Profile

A Phase 1 Study of Durvalumab and IPH2201 in Adult Subjects With Select Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Oct 2017

At a glance

  • Drugs Durvalumab (Primary) ; Monalizumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors MedImmune
  • Most Recent Events

    • 04 Oct 2017 Planned primary completion date changed from 30 Sep 2019 to 30 Oct 2019.
    • 01 Sep 2017 Planned number of patients changed from 175 to 208.
    • 01 Sep 2017 Planned End Date changed from 30 Aug 2019 to 30 Oct 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top